[an error occurred while processing this directive] | [an error occurred while processing this directive]
Clinical efficacy of hypofractionated radiotherapy for patients with locally advanced or advanced non-small cell lung cancer
Zhang Jiajia, Cao Yipeng, Chen Siying, Wang Jun, Zhao Lujun, Wang Ping, Liu Ningbo
Department of Radiation Oncology, Cancer Hospital of Tianjin Medical University, National Cancer Clinical Medical Research Center, Tianjin "Tumor Prevention and Control" Key Laboratory, Tianjin Malignant Tumor Clinical Medicine Research Center, Tianjin 300060, China
AbstractObjective To evaluate the survival outcome and toxicity of hypofractionated radiotherapy (45Gy/15f) in patients with locally advanced/advanced non-small cell lung cancer (NSCLC) who are ineligible for conventional fractionated radiotherapy. Methods The early efficacy, survival and toxicity of inoperable patients (n=64) with locally advanced/advanced NSCLC patients admitted to Cancer Hospital of Tianjin Medical University from 2014 to 2018 were retrospectively analyzed. Hypofractionated radiotherapy (45Gy/15f) were performed by using intensity-modulated radiotherapy or volumetric-modulated arc therapy technologies on Pinnacle 9 planning system. Results The median follow-up time was 26 months. The early efficacy was available in 58 patients:complete response for 2 cases (3%), partial response for 22(38%), stable disease for 28(44%) and progressive disease for 6(9%), respectively. The local control rate was 90%. The median time to progression (TTP) and the median overall survival (OS) for all patients was 8.2 months and 21.0 months, respectively. The 1-, 2-and 3-year TTP rate was 37%, 28%, 14% and the OS rate was 66%, 43% and 27%, respectively. The incidence of esophagitis was 17%(n=11), 19%(n=12) for radiation pneumonitis and 20%(n=13) for myelosuppression. No grade ≥3 esophagitis or pneumonia was found. Conclusion Hypofractionated radiotherapy (45Gy/15f) is efficacious and safe for patients with locally advanced/advanced NSCLC, which yields controllable adverse events.
Fund:National Nature Science Foundation of China (81372518);Surface Project of Tianjin Science and Technology Commission (16JCYBJC25300)
Corresponding Authors:
Liu Ningbo, Email:liuningbo@tjmuch.com
Cite this article:
Zhang Jiajia,Cao Yipeng,Chen Siying et al. Clinical efficacy of hypofractionated radiotherapy for patients with locally advanced or advanced non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(10): 1002-1006.
Zhang Jiajia,Cao Yipeng,Chen Siying et al. Clinical efficacy of hypofractionated radiotherapy for patients with locally advanced or advanced non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(10): 1002-1006.
[1] Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends—an update[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(1):16-27. DOI:10.1158/1055-9965. EPI-15-0578. [2] Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(13):2181-2190. DOI:10.1200/JCO.2009.26.2543. [3] Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage Ⅲ non-small cell lung cancer[J]. World J Clin Oncol, 2017, 8(1):1-20. DOI:10.5306/wjco.v8.i1.1. [4] Nguyen LN, Komaki R, Allen P, et al. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis:a retrospective review[J]. Int J Radiat Oncol Biol Phys, 1999, 44(5):1053-1056. DOI:10.1016/s0360-3016(99)00130-3. [5] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247. [6] Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage ⅢA or ⅢB non-small-cell lung cancer (RTOG 0617):a randomised, two-by-two factorial phase 3study[J]. Lancet Oncol, 2015, 16(2):187-199. DOI:10.1016/S1470-2045(14)71207-0. [7] Kaster TS, Yaremko B, Palma DA, et al. Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer:a systematic review of the literature[J]. Clin Lung Cancer, 2015, 16(2):71-79. DOI:10.1016/j.cllc.2014.08.002. [8] Strøm HH, Bremnes RM, Sundstrøm SH, et al. Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy:a subset analysis from a randomized clinical phase Ⅲ trial[J]. J Thorac Oncol, 2014, 9(6):825-833. DOI:10.1097/JTO.0000000000000184. [9] Amini A, Lin SH, Wei C, et al. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer[J]. Radiat Oncol, 2012, 7:33. DOI:10.1186/1748-717X-7-33. [10] Wigren T, Kellokumpu-Lehtinen P, Ojala A. Radical radiotherapy of inoperable non-small cell lung cancer. Irradiation techniques and tumor characteristics in relation to local control and survival[J]. Acta Oncol, 1992, 31(5):555-561. DOI:10.3109/0284186920908 8306. [11] Trovò MG, Minatel E, Veronesi A, et al. Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study[J]. Cancer, 1990, 65(3):400-404. DOI:10.1002/1097-0142(19900201)65:3<400::aid-cncr2820650304>3.0.co;2-h. [12] Puri S, Saltos A, Perez B, et al. Locally advanced, unresectable non-small cell lung cancer[J]. Curr Oncol Rep, 2020, 22(4):31. DOI:10.1007/s11912-020-0882-3. [13] Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma[J]. Int J Radiat Oncol Biol Phys, 2002, 52(1):49-57. DOI:10.1016/s0360-3016(01)01772-2. [14] Basaki K, Abe Y, Aoki M, et al. Prognostic factors for survival in stage Ⅲ non-small-cell lung cancer treated with definitive radiation therapy:impact of tumor volume[J]. Int J Radiat Oncol Biol Phys, 2006, 64(2):449-454. DOI:10.1016/j.ijrobp.2005.07.967. [15] Wang Z, Zhan P, Lv Y, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy:a meta-analysis[J]. Transl Lung Cancer Res, 2019, 8(3):214-226. DOI:10.21037/tlcr.2019.06.10. [16] Hui R,öagüroğlu M,Villegas A, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage Ⅲ, unresectable non-small-cell lung cancer (PACIFIC):a randomised, controlled, phase 3 study[J]. Lancet Oncol, 2019, 20(12):1670-1680. DOI:10.1016/S1470-2045(19)30519-4. [17] Gray JE, Villegas A, Daniel D, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC-update from PACIFIC[J]. J Thorac Oncol, 2020, 15(2):288-293. DOI:10.1016/j.jtho.2019.10.002.
2021, Vol. 30 
